AstraZeneca Expands ADC Portfolio with $600M Deal with LaNova
BIOMARKER
1. AstraZeneca strikes a $600M deal with LaNova Medicines for a preclinical stage ADC.
2. LaNova will get upfront payments of up to $55 million for LM-305, with an additional $545 million in potential milestones and royalties.
3. LM-305 has potential to become a first-in-class GPRC5D-directed ADC for multiple myeloma.
4. AstraZeneca halted development of MEDI2228, an anti-BCMA ADC for multiple myeloma in 2021.
5. AstraZeneca’s global head of multiple myeloma says the LaNova deal enriches their growing haematology pipeline.
6. AstraZeneca has experience with Enhertu, a HER2-directed ADC, approved for unresectable or metastatic breast cancer in 2019, and later for gastric cancer and NSCLC.
7. Enhertu made blockbuster status last year with sales over $1 billion.
8. AstraZeneca had already struck an ADC deal earlier this year for another Chinese-developed ADC.
9. Eight ADCs were approved by the FDA between 2019 and 2022.
10. ADC development is complex and reduces the chances of biosimilars hitting the market.